Figure 4

Induction of survivin-C58 peptide-specific CTLs and their cytotoxicity against survivin-positive cancer cell lines. CTLs were induced from PBMCs of an HLA-A*2402⁺ breast cancer patient by stimulating with survivin-C58 peptide-pulsed APCs. After four times stimulation, CTLs were subjected to standard ⁵¹Cr release assay at the indicated effector/target (E/T) ratio. In the left panel, T2-A24 cells and C1R-A31 cells were pulsed with or without survivin-C58 peptide (C58) or SYT-SSX-derived SS393 peptide (SYT), serving as target cells. In the right panel, survivin-positive breast cancer cell lines with HLA-A*2402 (HMC1 and HMC2) or without HLA-A*2402 (MCF7 and K562) were used as target cells. (A) CTLs were induced from PBMCs of an HLA-A*2402⁺ oral cancer patient (case #13 in Table 1) by stimulating with survivin-C58 peptide-pulsed APCs. After four times stimulation, CTLs were subjected to standard ⁵¹Cr release assay at the indicated effector/target (E/T) ratio. In the left panel, T2-A24 cells were pulsed with or without survivin-C58 peptide (C58), serving as target cells. In the right panel, survivin-positive HLA-A*2402-negative oral cancer cells (OSC20) and OSC20 transfectants with HLA-A*2402 cDNA (OSC20-A24) were used as target cells.